title: Nitric oxide metabolites: associations with cardiovascular biomarkers and clinical parameters in patients with HFpEF
Creators: name: Piatek, Karsten
name: Feuerstein, Anna
name: Zach, Veronika
name: Rozados Da Conceicao, Cristina
name: Beblo, Amelie
name: Belyavskiy, Evgeny
name: Pieske‐Kraigher, Elisabeth
name: Krannich, Alexander
name: Schwedhelm, Edzard
name: Hinz, Sarah
name: Pieske, Burkert
name: Edelmann, Frank
Publisher: name: Charité - Universitätsmedizin Berlin
Year: 2022
Subjects: subject: HFpEF
subject: Nitric oxide
subject: Arginine
subject: SDMA
subject: Endothelial dysfunction
classificationCode: 610
subject: Medizin und Gesundheit

description: Aims: Heart failure with preserved ejection fraction (HFpEF) is one of the most rapidly growing cardiovascular health burden worldwide, but there is still a lack of understanding about the HFpEF pathophysiology. The nitric oxide (NO) signalling pathway has been identified as a potential key element. The aim of our study was to investigate markers of NO metabolism [L-arginine (L-Arg), homoarginine (hArg), and asymmetric and symmetric dimethylarginine (ADMA and SDMA)], additional biomarkers [N-terminal pro-B-type natriuretic peptide (NT-proBNP), endothelin-1 (ET-1), mid-regional pro-adrenomedullin (MR-proADM), copeptin, and high-sensitivity C-reactive protein (hsCRP)], and the endothelial function in an integrated approach focusing on associations with clinical characteristics in patients with HFpEF. Methods and results: Seventy-three patients, prospectively enrolled in the 'German HFpEF Registry', were analysed. Inclusion criteria were left ventricular ejection fraction (LVEF) ≥ 50%; New York Heart Association functional class &gt;= II; elevated levels of NT-proBNP &gt; 125 pg/mL; and at least one additional criterion for structural heart disease or diastolic dysfunction. All patients underwent transthoracic echocardiography, cardiopulmonary exercise testing, and pulse amplitude tonometry (EndoPAT (TM)). Patients were categorized in two groups based on their retrospectively calculated HFA-PEFF score. Serum concentrations of l-Arg, hArg, ADMA, SDMA, NT-proBNP, ET-1, MR-proADM, copeptin, and hsCRP were determined. Patients had a median age of 74 years, 47% were female, and median LVEF was 57%. Fifty-two patients (71%) had an HFA-PEFF score ≥ 5 (definitive HFpEF), and 21 patients (29%) a score of 3 to 4 (risk for HFpEF). Overall biomarker concentrations were 126 +/- 32 mu mol/L for l-Arg, 1.67 +/- 0.55 mu mol/L for hArg, 0.74 (0.60;0.85) mu mol/L for SDMA, and 0.61 +/- 0.10 mu mol/L for ADMA. The median reactive hyperaemia index (RHI) was 1.55 (1.38;1.87). SDMA correlated with NT-proBNP (r = 0.291; P = 0.013), ET-1 (r = 0.233; P = 0.047), and copeptin (r = 0.381; P = 0.001). ADMA correlated with ET-1 (r = 0.250; P = 0.033) and hsCRP (r = 0.303; P = 0.009). SDMA was associated with the left atrial volume index (beta = 0.332; P = 0.004), also after adjustment for age, sex, and comorbidities. Biomarkers were non-associated with the RHI. A principal component analysis revealed two contrary clusters of biomarkers. Conclusions: Our findings suggest an impaired NO metabolism as one possible key pathogenic determinant in at least a subgroup of patients with HFpEF. We argue for further evaluation of NO-based therapies. Upcoming studies should clarify whether subgroups of HFpEF patients can take more benefit from therapies that are targeting NO metabolism and pathway.